## AMENDMENTS TO THE CLAIMS

Docket No.: 28967/5794C

This listing of claims will replace all prior versions, and listings, of claims in the applications:

## **Listing of Claims:**

- 1. (Currently amended) A method for activating at least one vascular endothelial growth factor selected from the group consisting of <u>purified VEGF-C</u> and <u>purified VEGF-D</u>, comprising treating said at least one vascular endothelial growth factor with a serine protease.
- 2. (Currently amended) [[A]] The method according to claim 1, wherein the serine protease is plasmin.
- 3. (Currently amended) [[A]] The method according to claim 1, wherein said at least one vascular endothelial growth factor is in an unprocessed form or a partially processed form.
- 4. (Currently amended) [[A]] <u>The</u> method according to claim 1, wherein said vascular endothelial growth factor is VEGF-D.
- 5. (Currently amended) [[A]] <u>The</u> method according to claim 1, wherein said vascular endothelial growth factor is VEGF-C.
  - 6-14. (Canceled)
- 15. (Currently amended) A method of treatment of a disorder selected from the group consisting of coronary artery disease, lymphedema, restenosis and stenosis comprising administering an effective amount of the pharmaceutical composition comprising an effective amount of a serine protease and a pharmaceutically acceptable excipient of claim 14 to a patient in need thereof.
  - 16-17. (Canceled)
  - 18. (New) The method according to claim 2, wherein the plasmin is purified.

Application No. 10/522,232 Docket No.: 28967/5794C Amendment dated October 16, 2007

Reply to Office Action of July 16, 2007

19. (New) A method for activating at least one vascular endothelial growth factor selected from the group consisting of VEGF-C and VEGF-D, comprising treating said at least one vascular endothelial growth factor with a purified serine protease.

- 20. (New) The method according to claim 19, wherein said at least one vascular endothelial growth factor is in an unprocessed form or a partially processed form.
- 21. (New) The method according to claim 19, wherein said vascular endothelial growth factor is VEGF-D.
- 22. (New) The method according to claim 19, wherein said vascular endothelial growth factor is VEGF-C.
  - 23. (New) The method according to claim 19, wherein the serine protease is plasmin.
- 24. (New) The method according to claim 15, wherein the composition is administered to said patient by local administration.
  - 25. (New) The method according to claim 15, wherein the serine protease is plasmin.

9